Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1999-06-24
2000-04-25
Elliott, George C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C12N 1585
Patent
active
060544406
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-2. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-2 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-2 are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
Butterfield et al., Stress- and cell type-dependent regulation of transfected c-Jun N- terminal kinase and mitogen-activated protein kinase kinase isoforms, Biochem. J., 1999, 338:681-686.
Cuenda et al., Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1, Biochem. J., 1998, 33:311-15.
Foltz et al., Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly conserved c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activated by envrionmental stresses and physiological stimuli, J. Biol. Chem., 1998, 273:9344-9351.
Hirai et al., Differential activation of two JNK activators, MKK7 and SEK1, by MKN28- derived nonreceptor serine/threonine kinase/mixed lineage kinase 2, J. Biol. Chem., 1988, 273:7406-7412.
Lu et al., Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38, J. Biol. Chem., 1997, 272:24751-24754.
Matsuda et al., T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A, J. Biol. Chem., 1998, 273:12378-12382.
Tournier et al., The MKK7 gene encodes a group of c-Jun NH2-terminal kinase kinases, Mol. Cell. Biol., 1999, 19:1569-1581.
Toyoshima et al., Fas induces cytoplasmic apoptotic responses and activation of the MKK7- JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases, J. Cell. Biol., 1997, 139:1005-1015.
Wu et al., Molecular cloning and characterization of human JNKK2, a novel Jun NH2- terminal kinase-specific kinase, Mol. Cell. Biol., 1997, 17:7407-7416.
Yamauchi et al., Differential regulation of mitogen-activated protein kinase kinase 4 (MKK4) and 7 (MKK7) by signaling from G protein beta gamma subunit in human embryonal kidney 293 cells, J. Biol. Chem., 1999, 274:1957-1965.
Yang et al., Molecular cloning and characterization of a human protein kianse that specifically activates c- Jun N-termainal kinase, Gene, 1998, 212:95-102.
James, Antiviral Chemistry & Chemotherapy (1991) 2(4), 191-214.
Crooke et al Antisense Applications & Research (1993), pp. 273-288.
Milner et al, Nature Biotechnology, 15, 1997, pp. 537-541.
Cowsert Lex M.
Monia Brett P.
Elliott George C.
Isis Pharmaceuticals , Inc.
Lacourciere Karen A
LandOfFree
Antisense inhibition of Jun N-terminal Kinase Kinase-2 expressio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense inhibition of Jun N-terminal Kinase Kinase-2 expressio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense inhibition of Jun N-terminal Kinase Kinase-2 expressio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993456